Repligen Corp (RGEN): Total Liabilities
$843.57M
As of 2025-12-31
$838.15M
As of 2026-06-30
+10.8%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $843.57M | -1.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $856.95M | -1.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $866.34M | +39.5% | 2025-03-14, Balance as of period end |
| 2022-12-31 | $620.90M | n/c | 2024-11-18, Balance as of period end |
| 2021-12-31 | $608.29M | +62.8% | 2023-02-22, Balance as of period end |
| 2020-12-31 | $373.74M | +9.8% | 2022-02-17, Balance as of period end |
| 2019-12-31 | $340.35M | +114.0% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $159.05M | +4.7% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $151.97M | n/a | 2019-03-01, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.92M | +5.2% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.30B | -40.3% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $218.73M | +43.5% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $686.24M | +5.8% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.48B | +45.7% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $114.23M | +4.4% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $168.90M | +19.3% |
Compare RGEN, BCRX, ADMA, NVAX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗